Precision BioSciences Inc (DTIL)
12.33
+0.35
(+2.92%)
USD |
NASDAQ |
May 17, 16:00
12.33
0.00 (0.00%)
After-Hours: 20:00
Precision BioSciences Enterprise Value: -29.43M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | -29.43M |
| May 16, 2024 | -32.34M |
| May 15, 2024 | -31.58M |
| May 14, 2024 | -34.83M |
| May 13, 2024 | -35.66M |
| May 10, 2024 | -41.62M |
| May 09, 2024 | -39.61M |
| May 08, 2024 | -37.25M |
| May 07, 2024 | -42.10M |
| May 06, 2024 | -41.48M |
| May 03, 2024 | -42.45M |
| May 02, 2024 | -40.33M |
| May 01, 2024 | -42.82M |
| April 30, 2024 | -43.31M |
| April 29, 2024 | -47.25M |
| April 26, 2024 | -50.43M |
| April 25, 2024 | -48.08M |
| April 24, 2024 | -47.39M |
| April 23, 2024 | -44.55M |
| April 22, 2024 | -48.36M |
| April 19, 2024 | -47.94M |
| April 18, 2024 | -41.16M |
| April 17, 2024 | -35.70M |
| April 16, 2024 | -26.29M |
| April 15, 2024 | -24.98M |
| Date | Value |
|---|---|
| April 12, 2024 | -17.65M |
| April 11, 2024 | -15.37M |
| April 10, 2024 | -17.72M |
| April 09, 2024 | -19.59M |
| April 08, 2024 | -21.73M |
| April 05, 2024 | -16.61M |
| April 04, 2024 | -16.13M |
| April 03, 2024 | -8.520M |
| April 02, 2024 | -17.10M |
| April 01, 2024 | -9.004M |
| March 31, 2024 | -21.52M |
| March 28, 2024 | -0.4823M |
| March 27, 2024 | -4.494M |
| March 26, 2024 | -6.084M |
| March 25, 2024 | -12.65M |
| March 22, 2024 | -13.90M |
| March 21, 2024 | -11.55M |
| March 20, 2024 | -13.99M |
| March 19, 2024 | -15.50M |
| March 18, 2024 | -17.27M |
| March 15, 2024 | -20.29M |
| March 14, 2024 | -22.65M |
| March 13, 2024 | -18.32M |
| March 12, 2024 | -15.43M |
| March 11, 2024 | -17.60M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-89.17M
Minimum
Mar 24 2023
798.29M
Maximum
Feb 08 2021
183.93M
Average
157.60M
Median
Enterprise Value Benchmarks
| Altimmune Inc | 385.90M |
| BioVie Inc | 9.577M |
| Adial Pharmaceuticals Inc | 3.458M |
| Gritstone Bio Inc | 79.51M |
| Humacyte Inc | 638.30M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 8.588M |
| Revenue (Quarterly) | 17.58M |
| Total Expenses (Quarterly) | 21.77M |
| EPS Diluted (Quarterly) | 1.70 |
| Profit Margin (Quarterly) | 48.84% |
| Earnings Yield | -59.35% |
| Normalized Earnings Yield | -74.17 |